
    
      This is a double-blind, placebo-controlled, randomized, parallel group study. Three different
      doses of APD356 or placebo will be administered daily for 12 weeks, to obese, male and
      nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects
      will be enrolled.
    
  